In this review, we provide an update on the current knowledge of non ABL-directed inhibitors and immunological-targeting approaches as treatment strategies for CML patients achieving unsatisfactory responses to TKIs. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.